StockData

Medline vs Stryker

MDLN and SYK side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MDLN and SYK compare

Stryker is the larger company, worth 2.4 times as much as Medline ($121B against $49.5B).

Stryker pays a dividend yielding 1.1%; Medline does not pay one.

Stryker scores higher on the StockData Score (18 against 2 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMDLNSYK
Size and price
Market cap$49.5B$121B
Share price$37.68$317.54
Change, 1 year–−12.3%
Change, 5 years–30.4%
Beta (5Y)–−0.03
Employees45K56K
StockData Score
Total score218 (better)
Valuation score03 (better)
Growth score15 (better)
Performance score03 (better)
Health score14 (better)
Dividend score03 (better)
Valuation
P/E–33.8×
P/S1.6× (better)4.6×
P/B4.2×–
EV/EBITDA23.8×18.8× (better)
P/FCF26.1× (better)26.4×
PEG–3.12
FCF yield3.8% (better)3.8%
Fair value$23.57$338.51
Margin of safety−59.8%6.2% (better)
Growth
Revenue growth (TTM)–7.9%
Revenue growth, 5Y average–11.8%
Net income growth (TTM)–23.1%
EPS growth (TTM)–23.4%
EPS growth, 5Y average–14.9%
Profitability
Gross margin25.7%65.3% (better)
Operating margin5.7%20.7% (better)
Net margin–13.8%
FCF margin6.2%17.4% (better)
Return on invested capital6.6%–
Financial health
Debt / equity1.07–
Net debt / EBITDA3.241.65 (better)
Interest coverage2.5×9.3× (better)
Current ratio4.04 (better)2.18
Altman Z-score2.634.81 (better)
Piotroski F-score–5
Dividends and buybacks
Dividend yield–1.1%
Payout ratio–36.8%
Buyback yield0.00%–
Shareholder yield0.00%1.1% (better)
Ownership
Held by institutions57.1%80.9%
Held by insiders81.9%4.2%
Insider net buying, 12 months−$14.3B−$580M (better)
Superinvestors holding4 (better)1
Short interest, % of float15.9%1.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.